Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 801–900 of 1,019

Dopamine transporter relation to levodopa‐derived synaptic dopamine in a rat model of Parkinson’s: an in vivo imaging study
Sossi, V., Dinelle, K., Topping, G. J., Holden, J. E., Doudet, D. J., Schulzer, M., Ruth, T. J., Stoessl, A. J., & de la Fuente‐Fernández, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05904.x · Cited by 54
“Parkinson’s disease (PD), which affects approximately 300/ 100 000 of the general population (de Lau and Breteler 2006), is characterized by a progressive degeneration of the dopaminergic system leading to increasingly severe dopamine (DA) deficiency resulting in debilitating motor and often…”
Background
Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson's disease
Scalzo, P. L., Flores, C. R., Marques, J. R., Robini, S. C. D. O., & Teixeira, A. L. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012000200009 · Cited by 54
Clinical Characteristics of Exacerbations in Parkinson Disease
Zheng, K. S., Dorfman, B. J., Christos, P. J., Khadem, N. R., Henchcliffe, C., Piboolnurak, P., & Nirenberg, M. J. (2012) · The Neurologist · doi:10.1097/nrl.0b013e318251e6f2 · Cited by 54
A National Registry to Determine the Distribution and Prevalence of Parkinson’s Disease in Thailand: Implications of Urbanization and Pesticides as Risk Factors for Parkinson’s Disease
Bhidayasiri, R., Wannachai, N., Limpabandhu, S., Choeytim, S., Suchonwanich, Y., Tananyakul, S., Tharathep, C., Panjapiyakul, P., Srismith, R., Chimabutra, K., et al. (2011) · Neuroepidemiology · doi:10.1159/000334440 · Cited by 54
ASK1 Overexpression Accelerates Paraquat-Induced Autophagy via Endoplasmic Reticulum Stress
Niso‐Santano, M., Pedro, J. M. B., Gómez‐Sánchez, R., Climent, V. E., Soler, G., Fuentes, J. M., & González‐Polo, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq313 · Cited by 55
Genetic Variants in MicroRNAs and Their Binding Sites Are Associated with the Risk of Parkinson Disease
Ghanbari, M., Darweesh, S. K. L., de Looper, H. W. J., van Luijn, M. M., Albert Hofman, D., Ikram, M. A., Franco, O. H., Erkeland, S. J., & Dehghan, A. (2015) · Human Mutation · doi:10.1002/humu.22943 · Cited by 54
“Parkinson disease (PD) is the second most common neurodegenerative disorder [de Lau and Breteler, 2006], and its prevalence and burden at the population level are projected to grow dramatically as the size of elderly population increases [Dorsey et al., 2007].”
Background
The significance of uric acid in the diagnosis and treatment of Parkinson disease
Yu, Z., Zhang, S., Wang, D., Fan, M., Gao, F., Sun, W., Li, Z., & Li, S. (2017) · Medicine · doi:10.1097/md.0000000000008502 · Cited by 53
Step length determines minimum toe clearance in older adults and people with Parkinson’s disease
Alcock, L., Galna, B., Perkins, R., Lord, S., & Rochester, L. (2017) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2017.12.002 · Cited by 55
“PD affects 1% of adults aged 60 years (de Lau and Breteler, 2006) and gait alterations are common (Morris et al., 1996; Hass et al., 2012; Galna et al., 2015) due to a range of motor impairments, including a reduced magnitude (hypokinesia) and speed (bradykinesia) of movement, axial rigidity and…”
Background
Application of the Movement Disorder Society prodromal criteria in healthy G2019S‐LRRK2 carriers
Mirelman, A., Saunders-Pullman, R. J., Alcalay, R. N., Shustak, S., Thaler, A., Gurevich, T., Raymond, D., Mejia‐Santana, H., Reilly, M. O., Ozelius, L. J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27342 · Cited by 54
Detecting neurodegenerative disorders from web search signals
White, R. W., Doraiswamy, P. M., & Horvitz, E. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0016-6 · Cited by 57
“INTRODUCTION Neurodegenerative disorders (NDs) are prevalent and a major source of healthcare expenditure.(1) NDs progress slowly,(2) and their symptoms may be subtle and mistaken for more common conditions.”
Background
Sex ratio in dementia with Lewy bodies balanced between Alzheimer’s disease and Parkinson’s disease dementia: a cross-sectional study
Mouton, A., Blanc, F., Gros, A., Manera, V., Fabre, R., Sauleau, E., Gomez-Luporsi, I., Tifratène, K., Friedman, L., Thümmler, S., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0417-4 · Cited by 52
Update on the Management of Parkinson’s Disease for General Neurologists
Pirtošek, Z., Bajenaru, O. A., Kovács, N., Milanov, I. G., Relja, M., & Škorvánek, M. (2020) · Parkinson s Disease · doi:10.1155/2020/9131474 · Cited by 54
“Parkinson’s disease (PD) is a disorder with increasing prevalence worldwide, and the second most common neurodegenerative disorder, surpassed only by Alzheimer’s disease [1, 2].”
Background
Pesticides and metals induced Parkinson's disease: involvement of free radicals and oxidative stress.
Singh, C., Ahmad, I., & Kumar, A. (2007) · PubMed · Cited by 54
Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model
Scheffold, A., Holtman, I. R., Dieni, S., Brouwer, N., Katz, S.-F., Jebaraj, B. M. C., Kahle, P. J., Hengerer, B., Lechel, A., Stilgenbauer, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0364-x · Cited by 53
“Parkinson’s disease (PD) is a neurodegenerative disease in the elderly with an average age of onset of 60 years, with 8-18/100,000 newly diagnosed patients every year [1].”
Background
Gray matter, white matter and cerebrospinal fluid abnormalities in Parkinson’s disease: A voxel-based morphometry study
Nyatega, C. O., Qiang, L., Adamu, M. J., & Kawuwa, H. B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1027907 · Cited by 53
Astrocytic modulation of neuronal signalling
Purushotham, S. S., & Buskila, Y. (2023) · Frontiers in Network Physiology · doi:10.3389/fnetp.2023.1205544 · Cited by 56
Selenium reduces bradykinesia and DNA damage in a rat model of Parkinson's disease
Ellwanger, J. H., Molz, P., Dallemole, D. R., dos Santos, A. P., Müller, T. E., Cappelletti, L., da Silva, M. G., Franke, S. I. R., Prá, D., & Henriques, J. A. P. (2014) · Nutrition · doi:10.1016/j.nut.2014.07.004 · Cited by 53
“3% among the general population in industrialized countries and about 1% among people>60 y of age [1,2].”
Background
Vocabulary influences older and younger listeners' processing of dysarthric speech
McAuliffe, M. J., Gibson, E. M. R., Kerr, S., Anderson, T., & LaShell, P. J. (2013) · The Journal of the Acoustical Society of America · doi:10.1121/1.4812764 · Cited by 53
Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons
Neuhaus, J., Baris, O. R., Heß, S., Moser, N., Schröder, H., Chinta, S. J., Andersen, J. K., Kloppenburg, P., & Wiesner, R. J. (2013) · Brain · doi:10.1093/brain/awt291 · Cited by 52
“Indeed, Parkinson’s disease is often referred to as an ageing disease, as its onset is at a mean age of 55 years and its incidence rises exponentially after 65 years (de Rijk et al., 1997; de Lau and Breteler, 2006).”
Background
Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Jahrling, J. B., & Laberge, R.-M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150610125856 · Cited by 55
GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease
Guan, J., Yang, B., Fan, Y., & Zhang, J. (2017) · Neuroimmunomodulation · doi:10.1159/000478908 · Cited by 53
PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway
Chiu, C., Yeh, T., Lu, C.-S., Huang, Y.-C., Cheng, Y., Huang, Y., Weng, Y.-H., Liu, Y.-C., Lai, S., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20893 · Cited by 55
Anti-Parkinsonian effects of β-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans
Wei, C., Chang, C., & Liao, V. H. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.09.002 · Cited by 54
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT)
Galeoto, G., Colalelli, F., Massai, P., Berardi, A., Tofani, M., Pierantozzi, M., Servadio, A., Fabbrini, A., & Fabbrini, G. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3524-x · Cited by 56
Apigenin exhibits anti-inflammatory effects in LPS-stimulated BV2 microglia through activating GSK3β/Nrf2 signaling pathway
Chen, P., Huo, X., Liu, W., Li, K., Sun, Z., & Tian, J. (2019) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2019.1688345 · Cited by 56
Automatic detection and quantification of hand movements toward development of an objective assessment of tremor and bradykinesia in Parkinson's disease
Pang, Y., Christenson, J., Jiang, F., Lei, T. C., Rhoades, R., Kern, D. S., Thompson, J. A., & Liu, C. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.108576 · Cited by 57
A 5-Year Follow-up Study on the Relationship between Obstructive Sleep Apnea and Parkinson Disease
Sheu, J., Lee, H., Lin, H., Kao, L., & Chung, S. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5274 · Cited by 53
Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease
Park, S. H., Park, C. W., Eom, J. H., Jo, M.-Y., Hur, H., Choi, S. K., Lee, J. S., Nam, S. T., Jo, K.-S., Oh, Y. W., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.009 · Cited by 52
DNA methylation in neurodegenerative disorders: a missing link between genome and environment?
Iraola‐Guzmán, S., Estivill, X., & Rabionet, R. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01673.x · Cited by 52
Stem cell-based approach for the treatment of Parkinson's disease.
Goodarzi, P., Aghayan, H. R., Larijani, B. A., Soleimani, M., Dehpour, A. R., Sahebjam, M., Ghaderi, F., & Arjmand, B. (2015) · PubMed Central · Cited by 52
Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
Lima, M. M. S., Targa, A., Noseda, A. C. D., Rodrigues, L. S., Delattre, A. M., dos Santos, F. V., Fortes, M., Maturana, M. J., & Ferraz, A. C. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660155 · Cited by 50
“Europe and the United States) [144].”
Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population
Chung, S. J., Jung, Y., Hong, M., Kim, M. J., You, S., Kim, Y. J., Kim, J., & Song, K. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.022 · Cited by 51
Association Between Tuberculosis and Parkinson Disease
Shen, C., Chou, C.-H., Liu, F., Lin, T., Huang, W., Wang, Y.-C., & Kao, C. (2016) · Medicine · doi:10.1097/md.0000000000002883 · Cited by 53
Parkinson Disease
Fritsch, T., Smyth, K. A., Wallendal, M. S., Hyde, T., Leo, G. J., & Geldmacher, D. (2012) · Southern Medical Journal · doi:10.1097/smj.0b013e318273a60d · Cited by 52
Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models
Hong, C., Chau, K., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep25344 · Cited by 52
ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON
Martínez‐Fernández, R., Gasca‐Salas, C., Sánchez‐Ferro, Á., & Obeso, J. A. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.06.010 · Cited by 52
Neuromuscular Impairments Are Associated With Impaired Head and Trunk Stability During Gait in Parkinson Fallers
Cole, M. H., Naughton, G. A., & Silburn, P. A. (2016) · Neurorehabilitation and neural repair · doi:10.1177/1545968316656057 · Cited by 52
“Parkinson’s disease (PD) is a heterogeneous neurodegenerative condition characterized by early symptoms of resting tremor,(1) slowness of movement,(2) and muscle rigidity.(2) However, with disease progression, patients may develop symptoms of postural instability(2) and difficulties with initiating and maintaining rhy…”
Background
Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign
Schmidt, M. A., Engelhorn, T., Marxreiter, F., Winkler, J., Lang, S., Kloska, S. P., Goelitz, P., & Doerfler, A. (2017) · BMC Neurology · doi:10.1186/s12883-017-0975-2 · Cited by 52
Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy
Moruno-Manchon, J. F., Uzor, N.-E., Kesler, S. R., Wefel, J. S., Townley, D. M., Nagaraja, A. S., Pradeep, S., Mangala, L. S., Sood, A. K., & Tsvetkov, A. S. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.11.014 · Cited by 54
“Exposure to pesticides, herbicides, heavy metals and certain organic solvents dramatically increases the risk of developing Parkinson's disease (de Lau and Breteler, 2006).”
Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson’s Disease
Cruces‐Sande, A., Rodriguez-Perez, A. I., Herbello-Hermelo, P., Bermejo‐Barrera, P., Méndez‐Álvarez, E., Labandeira-García, J. L., & Soto‐Otero, R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1274-7 · Cited by 51
Contributions of VPS35 Mutations to Parkinson’s Disease
Rahman, A. A., & Morrison, B. E. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.006 · Cited by 55
Targeting the cholinergic system in Parkinson’s disease
Liu, C. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0380-z · Cited by 56
Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease
Qin, L., Min, S., Li, S., Pan, H., Zhong, J., Guo, J., Sun, Q., Yan, X., Chen, C., Tang, B., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.018 · Cited by 52
Retraction Note: Gene expression profiling analysis of the putamen for the investigation of compensatory mechanisms in Parkinson’s disease
Gao, L., Gao, H., Zhou, H., & Xu, Y. (2015) · BMC Neurology · doi:10.1186/s12883-015-0307-3 · Cited by 52
Retracted
Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients
Sidorova, Y. A., & Domanskyi, A. (2020) · Methods and Protocols · doi:10.3390/mps3040066 · Cited by 50
“4% in general population, and occurs more often in males and elderly people [18].”
Background
Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials
Cammisuli, D. M., Cignoni, F., Ceravolo, R., Bonuccelli, U., & Castelnuovo, G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.798191 · Cited by 55
Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment
Yu, H., Sun, T., He, X., Wang, Z., Zhao, K., An, J., Wen, L., Li, J., Li, W., & Feng, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.0325 · Cited by 56
A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders
Mazibuko, Z., Choonara, Y. E., Kumar, P., du Toit, L. C., Modi, G., Naidoo, D., & Pillay, V. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24322 · Cited by 51
Neurosteroid and neurotransmitter alterations in Parkinson’s disease
di Michele, F., Luchetti, S., Bernardi, G., Romeo, E., & Longone, P. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.03.001 · Cited by 55
TheEIF4G1gene and Parkinson's disease
Deng, H., Wu, Y. Q., & Jankovic, J. J. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12397 · Cited by 51
Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology
Pan-Montojo, F. J., & Reichmann, H. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-10 · Cited by 54
Unmet Needs of Patients with Parkinson's Disease: Interview Survey of Patients and Caregivers
Hatano, T., Kubo, S.-I., Shimo, Y., Nishioka, K., & Hattori, N. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700315 · Cited by 51
Alterations of diffusion kurtosis and neurite density measures in deep grey matter and white matter in Parkinson’s disease
Surova, Y., Lampinen, B., Nilsson, M., Lätt, J., Hall, S., Widner, H., study, S. B., van Westen, D., & Hansson, O. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157755 · Cited by 51
Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine
Lins, L. C. R. F., Souza, M. F., Bispo, J. M. M., de Gois, A. M., Melo, T. C. D. S., Andrade, R. A. S., Quintans‐Júnior, L. J., Ribeiro, A. M., Silva, R. H., dos Santos, J. R., et al. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.01.017 · Cited by 51
Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease
Schröder, J. B., Marian, T., Claus, I., Muhle, P., Pawlowski, M., Wiendl, H., Suntrup‐Krueger, S., Meuth, S. G., Dziewas, R., Ruck, T., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00386 · Cited by 51
Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study
Picca, A., Calvani, R., Landi, G., Marini, F., Biancolillo, A., Gervasoni, J., Persichilli, S., Primiano, A., Urbani, A., Bossola, M., et al. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110766 · Cited by 51
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository
Gan‐Or, Z., Rao, T., Léveillé, E., Degroot, C., Chouinard, S., Cicchetti, F., Dagher, A., Das, S., Désautels, A., Drouin‐Ouellet, J., et al. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191775 · Cited by 56
“Parkinson’s disease (PD) is a common neurodegenerative, age-related movement disorder with a prevalence of 1-2% in individuals older than 60 years of age [1].”
Background
Perceptions of persons with Parkinson's disease, family and professionals on quality of life: an international focus group study
Oudsten, B. L. D., Lucas, R., Green, A. M., & The Whoqol-Dis Group (2011) · Disability and Rehabilitation · doi:10.3109/09638288.2011.575527 · Cited by 53
“Epidemiological estimates may vary, according to the applied methodology [1].”
BackgroundMethod
Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Increased Risk of Parkinson's Disease in Patients with End-Stage Renal Disease: A Retrospective Cohort Study
Wang, I., Lin, C., Wu, Y., Chou, C., Lin, S., Liu, J.-H., Yen, T., Huang, C.-C., & Sung, F. (2014) · Neuroepidemiology · doi:10.1159/000358921 · Cited by 50
Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinson’s Disease
Wang, R., Sun, H., Wang, G., & Ren, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197182 · Cited by 51
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting approximately 1% of the population over the age of 60 and, drastically, up to 5% of the population over 85 [1,2].”
Background
PINK1: A Bridge between Mitochondria and Parkinson’s Disease
Gonçalves, F. B., & Morais, V. A. (2021) · Life · doi:10.3390/life11050371 · Cited by 52
Phonemes based detection of parkinson’s disease for telehealth applications
Pah, N. D., Motin, M. A., & Kumar, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-13865-z · Cited by 51
Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.
Labandeira-García, J. L., Rodríguez‐Pallares, J., Villar‐Cheda, B., Rodriguez-Perez, A. I., Garrido‐Gil, P., & Guerra, M. J. (2011) · Europe PMC (PubMed Central) · Cited by 50
Analysis of blink rate in patients with blepharospasm
Bentivoglio, A. R., Daniele, A., Albanese, A., Tonali, P. A., & Fasano, A. A. (2006) · Movement Disorders · doi:10.1002/mds.20889 · Cited by 50
Activation of MAPK and FoxO by Manganese (Mn) in Rat Neonatal Primary Astrocyte Cultures
Exil, V. J., Li, P., Yu, Y., Chakraborty, S., Caito, S. W., Wells, K. S., Karki, P., Lee, E.-S., & Aschner, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094753 · Cited by 50
Parkinson’s disease and risk of hip fracture: An 8-year follow-up study in Taiwan
Chen, Y., Cheng, P., Wu, S., & Lai, C.-H. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.01.014 · Cited by 50
Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson’s Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators
Yasue, I., Matsunaga, S., Kishi, T., Fujita, K., & Iwata, N. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150818 · Cited by 50
“3 % and is positively associated with age [2–4].”
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
Tropea, T. F., Xie, S. X., Rick, J. H., Chahine, L. M., Dahodwala, N. A., Doshi, J. J., Davatzikos, C. A., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2017) · Movement Disorders · doi:10.1002/mds.27204 · Cited by 51
Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinson’s Disease
Blasberg, F., Wojtecki, L., Elben, S., Slotty, P. J., Vesper, J., Schnitzler, A., & Groiss, S. J. (2018) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12766 · Cited by 50
Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Qureshi, A. R., Rana, A. Q., Malik, S. H., Rizvi, S. F. H., Akhter, S., Vannabouathong, C., Sarfraz, Z., & Rana, R. (2018) · Neuroepidemiology · doi:10.1159/000492221 · Cited by 50
Radiomics approach in the neurodegenerative brain
Salvatore, C., Castiglioni, I., & Cerasa, A. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01299-z · Cited by 50
Cerebellar Transcranial Direct Current Stimulation in People with Parkinson’s Disease: A Pilot Study
Workman, C. D., Fietsam, A. C., Uc, E. Y., & Rudroff, T. (2020) · Brain Sciences · doi:10.3390/brainsci10020096 · Cited by 50
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the US [1], with total annual health care costs approaching 11 billion dollars [2].”
Background
Evaluating the Role of SNCA , LRRK2 , and GBA in Chinese Patients With Early‐Onset Parkinson's Disease
Chen, Y., Gu, X., Ou, R., Zhang, L., Hou, Y., Liu, K., Cao, B., Wei, Q., Li, C., Song, W., et al. (2020) · Movement Disorders · doi:10.1002/mds.28191 · Cited by 50
Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences
Utsumi, K., Fukatsu, R., Yamada, R., Takamaru, Y., Hara, Y., & Yasumura, S. (2020) · Psychogeriatrics · doi:10.1111/psyg.12586 · Cited by 50
Sparse Adaptive Graph Convolutional Network for Leg Agility Assessment in Parkinson’s Disease
Guo, R., Shao, X., Zhang, C., & Qian, X. (2020) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2020.3039297 · Cited by 51
Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson’s disease? A critical reappraisal
Subrahmanian, N., & LaVoie, M. J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147434 · Cited by 48
DJ-1 inhibits microglial activation and protects dopaminergic neurons in vitro and in vivo through interacting with microglial p65
Lin, Z., Chen, C., Yang, D., Ding, J., Wang, G., & Ren, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04002-1 · Cited by 49
Autonomic dysfunction: Diagnosis and management
Rafanelli, M., Walsh, K., Hamdan, M. H., & Buyan‐Dent, L. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00008-x · Cited by 49
Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research
Rajan, R., Divya, K. P., Kandadai, R. M., Yadav, R., Satagopam, V., Madhusoodanan, U. K., Agarwal, P. A., Kumar, N., Ferreira, T., Kumar, H., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00524 · Cited by 51
The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis
Narmashiri, A., Abbaszadeh, M., & Ghazizadeh, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104792 · Cited by 49
Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Mihaescu, A. S., Valli, M., Uribe, C., Díez‐Cirarda, M., Masellis, M., Graff‐Guerrero, A., & Strafella, A. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00964-1 · Cited by 53
Prediction of Parkinson’s Disease Using Machine Learning Methods
Zhang, J., Zhou, W., Yu, H., Wang, T., Wang, X., Liu, L., & Wen, Y. (2023) · Biomolecules · doi:10.3390/biom13121761 · Cited by 52
Transcranial photobiomodulation for brain diseases: review of animal and human studies including mechanisms and emerging trends
Lin, H. R., Li, D., Zhu, J., Liu, S., Li, J., Yu, T., Tuchin, V. V., SEMYACHKINA-GLUSHKOVSKAYA, O. V., & Zhu, D. Y. (2024) · Neurophotonics · doi:10.1117/1.nph.11.1.010601 · Cited by 60
Taste function in early stage treated and untreated Parkinson’s disease
Doty, R. L., Nsoesie, M. T., Chung, I., Osman, A., Pawasarat, I. M., Caulfield, J., Hurtig, H. I., Silas, J., Dubroff, J. G., Duda, J. E., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7589-z · Cited by 49
Diffusion tensor imaging and correlations to Parkinson rating scales
Lenfeldt, N., Hansson, W., Larsson, A., Nyberg, L. H., Birgander, R., & Forsgren, L. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7080-2 · Cited by 49
Lack of association of dairy food, calcium, and vitamin D intake with the risk of Parkinson’s disease: A case-control study in Japan
Miyake, Y., Tanaka, K., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.11.018 · Cited by 49
“Various food groups and specific nutrients have been investigated as potential risk factors for PD [2].”
Background
Effects of dopaminergic therapy on locomotor adaptation and adaptive learning in persons with Parkinson's disease
Roemmich, R. T., Hack, N. K., Akbar, U., & Hass, C. J. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.041 · Cited by 50
Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., & Sossi, V. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.04.008 · Cited by 49
“Parkinson’s disease (PD) is a degenerative disorder that affects some 1e2% of the general population over the age of 60 years, and can reach a prevalence of 4% in people older than 90 years of age [1].”
Cardiovascular physiology in premotor Parkinson's disease: A neuroepidemiologic study
Jain, S., Ton, T. G. N., Perera, S., Zheng, Y., Stein, P. K., Thacker, E. L., Strotmeyer, E. S., Newman, A. B., & Longstreth, W. T. (2012) · Movement Disorders · doi:10.1002/mds.24979 · Cited by 48
Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development
Hargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 54
“PD is the second most common neurodegenerative disease and affects approximately 1 % of people over 60 years of age and approximately 4 % of people over 80 years of age [50].”
Background
Scalp acupuncture for Parkinson’s disease: A systematic review of randomized controlled trials
Lee, H.-S., Park, H.-L., Lee, S., Shin, B., Choi, J., & Lee, M. S. (2013) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-013-1431-9 · Cited by 49
Smartphone application for classification of motor impairment severity in Parkinson's disease
Printy, B. P., Renken, L. M., Herrmann, J. P., Lee, I., Johnson, B., Knight, E. J., Varga, G., & Whitmer, D. (2014) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2014.6944176 · Cited by 49
Gene Expression Differences in Peripheral Blood of Parkinson’s Disease Patients with Distinct Progression Profiles
Pinho, R., Guedes, L. C., Soreq, L., Lobo, P. P., Mestre, T., Coelho, M. M., Rosa, M. M., Gonçalves, N., Wales, P., Mendes, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157852 · Cited by 49
“Parkinson’s Disease (PD) is a multi-system, disabling, insidiously progressive neurodegenerative condition affecting 1–2% of the population over the age of 60 [1].”
Background
Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity
Brehme, M., & Voisine, C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024703 · Cited by 54
“Aging correlates with cognitive decline and represents the most significant risk factor for dementia and neurodegenerative diseases (Brookmeyer et al., 1998; Hof and Morrison, 2004; de Lau and Breteler, 2006).”
Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits
Zhou, L., Wang, W., Hoppel, C. L., Liu, J., & Zhu, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.032 · Cited by 49
Adipose-derived Stem Cells Stimulated with n -Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinson’s Disease
Chi, K., Fu, R., Huang, Y.-C., Chen, S., Hsu, C.-J., Lin, S., Tu, C.-T., Chang, L.-H., Wu, P.-A., & Liu, S. (2018) · Cell Transplantation · doi:10.1177/0963689718757408 · Cited by 49
Cancer risk in patients with Parkinson’s disease in South Korea: A nationwide, population-based cohort study
Park, J., Kim, D., Park, Y. G., Kwon, D., Choi, M., Jung, J., & Han, K. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.033 · Cited by 49
Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson's disease
Wang, C., Shi, H.-H., Xu, J., Yanagita, T., Xue, C., Zhang, T., & Wang, Y. (2020) · Food & Function · doi:10.1039/d0fo01176b · Cited by 49
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Liu, J., Xu, F., Nie, Z., & Shao, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570658 · Cited by 52

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks